Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer

Overview of attention for article published in Annals of Surgical Oncology, May 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter: 21 X users

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 22 X posts from 21 X users, with an upper bound of 264,631 followers.

RT @AJRossiMD: Pleased to share this interesting study looking at targeting SEMA4D +/- immunotherapy, the next installment of the series an…

RT @theNCI: Can the #ColorectalCancer tumor microenvironment be altered with a combination of immunotherapy and drugs that target SEMA4D? h…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 18 additional X posts.